Galectin Therapeutics/$GALT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Primary listing
Employees
15
Headquarters
Website
GALT Metrics
BasicAdvanced
$295M
-
-$0.64
0.83
-
Price and volume
Market cap
$295M
Beta
0.83
52-week high
$4.71
52-week low
$0.73
Average daily volume
258K
Financial strength
Current ratio
1.432
Quick ratio
1.278
Long term debt to equity
-104.121
Total debt to equity
-104.165
Interest coverage (TTM)
-5.01%
Profitability
Management effectiveness
Return on assets (TTM)
-98.30%
Return on equity (TTM)
40.48%
Valuation
Price to book
-2.47
Price to tangible book (TTM)
-2.47
Price to free cash flow (TTM)
-8.126
Free cash flow yield (TTM)
-12.31%
Free cash flow per share (TTM)
-0.566
Growth
Earnings per share change (TTM)
-17.75%
3-year earnings per share growth (CAGR)
2.50%
10-year earnings per share growth (CAGR)
-1.95%
What the Analysts think about GALT
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
GALT Financial Performance
Revenues and expenses
GALT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $295M as of September 08, 2025.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of September 08, 2025.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of September 08, 2025.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.